Chronic Kidney Disease Mineral Bone Disorder (CKD-MBD)

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Seventh Edition

Volumn , Issue , 2009, Pages 343-349

  Hruska, Keith A ^a   Mathew, Suresh ^a  

^a Division of Pediatric Nephrology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84889490803     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470623992.ch73     Document Type: Chapter

References (39)

1. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G 2006 Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945-1953.
2. Mathew S, Lund R, Strebeck F, Tustison KS, Geurs T, Hruska KA 2007 Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy. J Am Soc Nephrol 18:122-130.
3. Davies MR, Lund RJ, Mathew S, Hruska KA 2005 Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 16:917-928.
4. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A 2004 Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15:770-779.
5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK 1998 Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31:607-617.
6. Lund RJ, Davies MR, Brown AJ, Hruska KA 2004 Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol 15:359-369.
7. Malluche HH, Ritz E, Lange HP 1976 Bone histology in incipient and advanced renal failure. Kidney Int 9:355-362.
8. Craver L, Marco MP, Martinez I, Rue M, Borras M, Martin ML, Sarro F, Valdivielso JM, Fernandez E 2007 Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achieve-ment of K/DOQI target ranges. Nephrol Dial Transplant 22:1 Hill 76.
9. Malluche HH, Faugere MC 1990 Renal bone disease 1990: Challenge for nephrologists. Kidney Int 38:193-211.
10. Foley RN. Parfrey PS, Sarnak MJ 1998 Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32:S112-S119.
11. Slinin Y, Foley RN, Collins AJ 2005 Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 16:1788-1793.
12. Slatopolsky E. Robson AM, Elkan I, Bricker NS 1968 Control of phosphate excretion in uremic man. J Clin Invest 47:1865-1874.
13. Kurz P, Monier-Faugere M-C, Bognar B, Werner E, Roth P, Vlachojannis J, Malluche HH 1994 Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 46:855-861.
14. Moallem E, Kilav R, Silver J, Naveh-Many T 1998 RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 273:5253-5259.
15. Naveh-Many T, Rahamimov R, Livni N, Silver J 1995 Parathyroid cell proliferation in normal and chronic renal failure rats. J Clin Invest 96:1786-1793.
16. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM 2000 Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87:el0-el7.
17. Li X, Yang HY, Giachelli CM 2006 Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 98:905-912.
18. Goodman WG, Quarles LD 2008 Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. Kidney Int 74:276-288.
19. Naveh-Many T, Marx R, Keshet E, Pike JW, Silver J 1990 Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest 86:1968-1975.
20. Silver J, Russell J, Sherwood LM 1985 Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci USA 82:4270-4273.
21. Brown EM. Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC 1993 Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366:575-580.
22. Brown EM, Hebert SC 1995 A cloned Ca2+ sensing receptor: A mediator of direct effects of extracellular Ca2+ on renal function? J Am Soc Nephrol 6:1530-1540.
23. The ADHR consortium, Group 1: White KE, Evans WE, O'Riordan JLH, Speer MC, Econs JJ, Groups 2: Lorenz-Depiereux B, Grabowski M, Meitinger T, Strom TM 2000 Auto-somal dominant hypophosphatemic rickets is associated with mu-tations in FGF23. Nat Genet 26:345-348.
24. White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljung-gren O, Meitinger T, Strom TM, Juppner H, Econs MJ 2001 The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting. J Clin Endocrinol Metab 86:497-500.
25. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279.
26. Andress DL, Sherrard DJ 2007 The osteodystrophy of chronic renal failure. In: Schrier RW (ed.) Diseases of the Kidney and Urinary Tract, 8th ed. Lippincott Williams & Wilkins, Philadelphia, PA, USA, pp. 2431-2459.
27. Alem AM, Sherrard DJ, Gillen DL, Weiss NS. Beresford SA, Heckbert SR, Wong C, Stehman-Breen C 2000 Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58:396-399.
28. Cunningham J, Sprague S. Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J 2004 Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566571.
29. Rix M, Andreassen H, Eskildsen P, Langdahl B, Olgaard K 1999 Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure. Kidney Int 56:1084-1093.
30. Stehman-Breen C 2001 Bone mineral density measurements in dialysis patients. Semin Dial 14:228-229.
31. Coco M, Rush H 2000 Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 36:1115-1121.
32. Mathew S, Tustison K, Sugatani T, Chaudhary LR, Rifas L, Hruska KA 2008 The mechanism of phosphorus as a cardiovascular risk factor in chronic kidney disease. J Am Soc Nephrol 19:1092-1105.
33. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T. Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL 2007 Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491.
34. Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ 2007 A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684-2691.
35. Ichikawa S, Lyles KW, Econs MJ 2005 A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: Evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab 90:2420-2423.
36. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390.
37. Schiavi SC, Kumar R 2004 The phosphatonin pathway: New insights in phosphate homeostasis. Kidney Int 65:1-14.
38. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M 2006 Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 281:6120-6123.
39. Eknoyan G, Levin A, Levin NW 2003 K/DOQI clinical practice guidelines on bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S12-S28;S52-S57.